• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用医疗索赔评估荷兰骨髓增生异常综合征和慢性粒单核细胞白血病的发病率、诊断程序和初始治疗。

The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands.

机构信息

Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.

Clinical Trial Center, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.

出版信息

Leuk Res. 2015 Feb;39(2):177-82. doi: 10.1016/j.leukres.2014.11.025. Epub 2014 Dec 4.

DOI:10.1016/j.leukres.2014.11.025
PMID:25533930
Abstract

Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) may be underreported in cancer registries such as the Netherlands Cancer Registry (NCR). Analysis of Dutch medical claims can complement NCR data on MDS and CMML. We analyzed data on 3681 MDS patients and 235 CMML patients aged ≥18 years with initial claims for MDS or CMML from the Dutch nationwide medical claims-based Diagnosis Treatment Combination Information System (DIS) between 2008 and 2010. Clinical information was available in the DIS. MDS and CMML were diagnosed without a bone marrow (BM) examination in almost half of the patients. The age-standardized incidence rate (ASR) per 100,000 in the cohort that underwent BM examinations compared with NCR data was 2.8 vs. 3.3 for MDS and 0.2 vs. 0.4 for CMML in 2008-2010. A conservative treatment approach was associated with increasing age and absence of BM examination in MDS (p<0.001 for both) and CMML patients (p<0.033 for both). In conclusion, the ASR of MDS in the cohort that underwent BM examinations was comparable with the NCR. The majority of elderly patients, either with or without BM examinations, received no therapy. Together, MDS and CMML may be misdiagnosed and inappropriately managed without a BM confirmation.

摘要

骨髓增生异常综合征(MDS)和慢性粒单核细胞白血病(CMML)在癌症登记处(如荷兰癌症登记处)可能报告不足。对荷兰医疗索赔的分析可以补充 MDS 和 CMML 的 NCR 数据。我们分析了 2008 年至 2010 年间来自荷兰全国性基于医疗索赔的诊断治疗组合信息系统(DIS)的 3681 例 MDS 患者和 235 例年龄≥18 岁的初始 MDS 或 CMML 索赔的 CMML 患者的数据。DIS 中提供了临床信息。在近一半的患者中,MDS 和 CMML 的诊断未进行骨髓(BM)检查。与 NCR 数据相比,接受 BM 检查的队列中的年龄标准化发病率(ASR)为每 10 万人 2.8 与 MDS 相比为 3.3,2008-2010 年为 0.2 与 CMML 相比为 0.4。在 MDS(均<0.001)和 CMML 患者中(均<0.033),保守治疗方法与年龄增加和缺乏 BM 检查相关。总之,接受 BM 检查的队列中 MDS 的 ASR 与 NCR 相当。大多数老年患者,无论是否进行 BM 检查,都未接受治疗。总之,MDS 和 CMML 可能未经 BM 确认而误诊和不当治疗。

相似文献

1
The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands.利用医疗索赔评估荷兰骨髓增生异常综合征和慢性粒单核细胞白血病的发病率、诊断程序和初始治疗。
Leuk Res. 2015 Feb;39(2):177-82. doi: 10.1016/j.leukres.2014.11.025. Epub 2014 Dec 4.
2
Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010.骨髓增生异常综合征发病、初始治疗和生存趋势的研究:荷兰 2001 至 2010 年间诊断的 5144 例患者的基于人群研究。
Eur J Cancer. 2014 Mar;50(5):1004-12. doi: 10.1016/j.ejca.2013.12.002. Epub 2013 Dec 31.
3
FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia.FLT3 突变在骨髓增生异常综合征和慢性粒单核细胞白血病中的作用。
Am J Hematol. 2013 Jan;88(1):56-9. doi: 10.1002/ajh.23345. Epub 2012 Oct 31.
4
Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.在荷兰阿扎胞苷同情用药计划中,第一个阿扎胞苷周期后血小板倍增是骨髓增生异常综合征(MDS)、慢性粒单核细胞白血病(CMML)和急性髓系白血病(AML)患者反应的有希望的预测指标。
Br J Haematol. 2011 Dec;155(5):599-606. doi: 10.1111/j.1365-2141.2011.08893.x. Epub 2011 Oct 8.
5
[Significance and application value of multiparameter flow cytometry for differentiation of immunophenotype in chronic myelomonocytic leukemia, myelodysplastic syndrome and acute monocytic leukemia].[多参数流式细胞术在慢性粒单核细胞白血病、骨髓增生异常综合征及急性单核细胞白血病免疫表型鉴别中的意义及应用价值]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Aug;20(4):857-62.
6
Asthma and risk of myelodysplastic syndromes: a population-based cohort study.哮喘与骨髓增生异常综合征风险:一项基于人群的队列研究。
Br J Cancer. 2017 Jan 3;116(1):100-102. doi: 10.1038/bjc.2016.389. Epub 2016 Nov 29.
7
Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia.慢性粒单核细胞白血病中的生存素表达、细胞凋亡与增殖
Eur J Haematol. 2006 Jun;76(6):494-501. doi: 10.1111/j.0902-4441.2006.t01-1-EJH2588.x. Epub 2006 Mar 9.
8
Immunophenotype in chronic myelomonocytic leukemia: is it closer to myelodysplastic syndromes or to myeloproliferative disorders?慢性粒单核细胞白血病的免疫表型:它更接近骨髓增生异常综合征还是骨髓增殖性疾病?
Transl Res. 2008 May;151(5):240-5. doi: 10.1016/j.trsl.2008.03.001. Epub 2008 Apr 7.
9
Telomerase activity in myelodysplastic syndromes.骨髓增生异常综合征中的端粒酶活性
Leuk Res. 2005 Oct;29(10):1131-9. doi: 10.1016/j.leukres.2005.03.006. Epub 2005 Apr 7.
10
Chronic myelomonocytic leukaemia (CMML)--a myelodysplastic or myeloproliferative syndrome?慢性粒单核细胞白血病(CMML)——一种骨髓增生异常综合征还是骨髓增殖性综合征?
Leuk Lymphoma. 1993 Jan;9(1-2):35-41. doi: 10.3109/10428199309148501.

引用本文的文献

1
Burden of myelodysplastic syndromes: a systematic literature review of economic burden.骨髓增生异常综合征的负担:经济负担的系统文献综述
Eur J Health Econ. 2025 Apr 23. doi: 10.1007/s10198-025-01779-2.
2
Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).日本 MDS 和 CMML 的真实世界数据:JALSG 临床观察研究-11(JALSG-CS-11)的结果。
Int J Hematol. 2024 Feb;119(2):130-145. doi: 10.1007/s12185-023-03686-9. Epub 2023 Dec 13.
3
Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).
日本 AML 的真实世界数据:JALSG 临床观察研究-11(JALSG-CS-11)的结果。
Int J Hematol. 2024 Jan;119(1):24-38. doi: 10.1007/s12185-023-03677-w. Epub 2023 Nov 28.
4
Myeloid NGS Analyses of Paired Samples from Bone Marrow and Peripheral Blood Yield Concordant Results: A Prospective Cohort Analysis of the AGMT Study Group.骨髓和外周血配对样本的髓系二代测序分析结果一致:AGMT研究组的前瞻性队列分析
Cancers (Basel). 2023 Apr 14;15(8):2305. doi: 10.3390/cancers15082305.
5
Chronic myelomonocytic leukemia in a 72-year-old male from Nepal: A case report.一名72岁尼泊尔男性的慢性粒单核细胞白血病:病例报告。
Ann Med Surg (Lond). 2023 Feb 7;85(2):257-260. doi: 10.1097/MS9.0000000000000198. eCollection 2023 Feb.
6
The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.ABNL-MARRO 001 研究:一项在 MDS/MPN 重叠综合征中随机分配活性髓系靶向化合物组合的 1-2 期研究。
BMC Cancer. 2022 Sep 24;22(1):1013. doi: 10.1186/s12885-022-10073-w.
7
Chronic Myelomonocytic Leukemia: Hematopathology Perspective.慢性粒单核细胞白血病:血液病理学视角
J Immunother Precis Oncol. 2021 Jun 18;4(3):142-149. doi: 10.36401/JIPO-21-1. eCollection 2021 Aug.
8
Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry.泊马度胺治疗复发和/或难治性多发性骨髓瘤患者:荷兰全国癌症登记处的一项前瞻性研究
Hemasphere. 2022 Jan 27;6(2):e683. doi: 10.1097/HS9.0000000000000683. eCollection 2022 Feb.
9
Incidence of myeloid neoplasms in Spain (2002-2013): a population-based study of the Spanish network of cancer registries.西班牙髓系肿瘤发病率(2002-2013 年):西班牙癌症登记处网络的一项基于人群的研究。
Sci Rep. 2022 Jan 10;12(1):323. doi: 10.1038/s41598-021-03734-6.
10
Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia.越来越多的认识和新兴疗法表明需要在慢性髓单核细胞白血病中进行专门的临床试验。
Leukemia. 2021 Oct;35(10):2739-2751. doi: 10.1038/s41375-021-01330-1. Epub 2021 Jun 26.